Sammanfattning av aktiekursernas upp- och nedgångar samt förändringar för Invivyd
Historiska aktiekurser
Aktuell aktiekurs	US$0.89
52 veckors högsta	US$3.07
52 veckors lägsta	US$0.48
Beta	0.67
1 månads förändring	-13.22%
3 månaders förändring	-31.25%
1 års förändring	21.59%
3 års förändring	-25.52%
5 års förändring	n/a
Förändring sedan börsintroduktionen	-95.72%

Senaste nyheter och uppdateringar

Uppdatering av berättelse • Jun 23

IVVD: Phase 3 Prophylaxis Readouts And BLA Prospect Will Drive Upside

Analysts have kept their $10.00 price target on Invivyd steady, citing the recent post earnings selloff as overdone, given that the Q1 revenue shortfall and higher $30.7 million research and development spend are viewed as timing related and tied to pivotal investments ahead of the key VYD2311 data readout and potential biologics license application. What’s in the News for Invivyd Invivyd completed enrollment in the Phase 3 DECLARATION trial of VYD2311, assessing a single intramuscular dose and monthly dosing versus placebo for prevention of symptomatic COVID-19 over 90 days, with approximately 2,400 participants enrolled.

Uppdatering av berättelse • Jun 05

IVVD: Phase 3 Prophylaxis Progress And BLA Pathway Will Drive Upside

Narrative Update on Invivyd Analysts have reaffirmed a $10 price target for Invivyd, citing the view that the recent post earnings selloff tied to a Q1 revenue miss and higher research and development spend was overdone. Upcoming VYD2311 data and a potential biologics license application are seen as the main drivers for maintaining this valuation level.

Recent updates

Uppdatering av berättelse • Jun 23

IVVD: Phase 3 Prophylaxis Readouts And BLA Prospect Will Drive Upside

Uppdatering av berättelse • Jun 05

IVVD: Phase 3 Prophylaxis Progress And BLA Pathway Will Drive Upside

Uppdatering av berättelse • Apr 26

IVVD: Phase 3 COVID Prophylaxis Progress Will Drive Future Upside

Analysts have adjusted their price target on Invivyd to reflect updated assumptions for discount rate, revenue growth, profit margin and future P/E. They are keeping fair value around $10.00 per share while fine tuning the risk and profitability profile that underpins the estimate.

Uppdatering av berättelse • Apr 11

IVVD: Phase 3 COVID Prophylaxis Progress Will Drive Future Upside

Analysts have adjusted their price target on Invivyd to $10.00 from $10.00, reflecting updated views on discount rate, revenue growth expectations, profit margin and future P/E assumptions. What's in the News Invivyd reported progress in the REVOLUTION clinical program for VYD2311, including the pivotal DECLARATION Phase 3 study assessing VYD2311 for pre-exposure COVID-19 prophylaxis versus placebo over 90 days, with a blinded sample size re-estimation that triggered an upsizing of approximately 500 subjects to support statistical power.

Uppdatering av berättelse • Mar 26

IVVD: Phase 3 COVID Prevention And Long COVID Trial Will Drive Upside

Narrative Update on Invivyd Analysts have modestly adjusted their price view on Invivyd, with the updated fair value holding at $10.00. Small tweaks to discount rate, revenue growth, profit margin assumptions, and a higher future P/E estimate of about 282x refine the underlying model rather than signal a major shift in conviction.

Seeking Alpha • Mar 20

Invivyd: A Logical Bull Thesis With A Major Catalyst Approaching

Summary Invivyd, Inc. is advancing VYD2311, a next-gen monoclonal antibody for COVID-19 prevention, with pivotal Phase 3 DECLARATION data expected mid-2026. IVVD's Pemgarda generated $53.4M in 2025 revenue, but fell short of management expectations; net loss narrowed to $(52.5M) from $(170M) prior year. IVVD secured FDA Fast Track for VYD2311 and raised ~$200M in 2H 2025, providing at least two years of funding at current burn rates. I view IVVD stock as a high-risk, high-reward opportunity; DECLARATION study success could drive shares up 75%, but failure could see stock revisit sub-$0.5 levels. Read the full article on Seeking Alpha

Uppdatering av berättelse • Mar 10

IVVD: Fast Track Phase 3 COVID Prevention Program Will Drive Future Upside

Analysts have adjusted their price target on Invivyd to reflect updated assumptions around revenue growth of 71.06%, a profit margin of 5.97% and a future P/E of 266.11x. These assumptions result in a revised fair value estimate of $10.00 per share.

Uppdatering av berättelse • Feb 23

IVVD: Phase 3 Fast Track COVID Prevention Trials Will Support Future Upside

Analysts have kept their fair value estimate for Invivyd steady at $10.00. A slightly lower discount rate and modestly softer profit margin outlook, paired with a marginally higher future P/E assumption, reflect a more finely balanced view of the company’s risk and earnings potential.

Uppdatering av berättelse • Feb 09

IVVD: Phase 3 Fast Track COVID Prevention Program Will Drive Future Upside

Analysts have trimmed their price target on Invivyd to US$10, citing updated assumptions that include a slightly higher discount rate, modestly reduced profit margin expectations, and a higher future P/E multiple. What's in the News FDA granted Fast Track designation for VYD2311, Invivyd's vaccine alternative monoclonal antibody candidate for prevention of COVID in individuals with underlying risk factors for severe disease, aligning the program with an expedited U.S. regulatory process (Key Developments).

Analysartikel • Jan 29

Invivyd, Inc.'s (NASDAQ:IVVD) 26% Share Price Plunge Could Signal Some Risk

The Invivyd, Inc. ( NASDAQ:IVVD ) share price has softened a substantial 26% over the previous 30 days, handing back...

Uppdatering av berättelse • Jan 24

IVVD: REVOLUTION Program Will Define Future Upside As COVID Prevention Alternative

Analysts have lifted their price target on Invivyd to US$10 from US$5, citing the launch of the REVOLUTION clinical program for VYD2311 as a key driver behind their updated view. Analyst Commentary Analysts are reacting to the REVOLUTION program for VYD2311 as a key event for Invivyd, and the updated US$10 price target reflects how they are recalibrating risk and potential upside around this new clinical path.

Uppdatering av berättelse • Jan 08

IVVD: REVOLUTION Program And Fast Track Status Will Support Future Upside Potential

Narrative Update on Invivyd Analysts have lifted their price target on Invivyd to US$10 from US$5, pointing to the launch of the REVOLUTION clinical program for VYD2311 as a key factor that they believe strengthens the company’s regulatory and commercial position. Analyst Commentary Recent Street research around Invivyd has focused squarely on the launch of the REVOLUTION clinical program for VYD2311, with bullish analysts recalibrating their expectations for the company’s potential market position and execution risk.

Uppdatering av berättelse • Dec 18

IVVD: REVOLUTION Program Launch Will Drive Future Regulatory And Commercial Upside

Analysts have raised their price target on Invivyd to $10 from $5, citing the launch of the REVOLUTION clinical program for VYD2311 as a meaningful inflection point that enhances the company’s regulatory and commercial outlook. Analyst Commentary Following the launch of the REVOLUTION clinical program for VYD2311, equity research has focused on how the new data and development path could reshape Invivyd's long term growth and valuation profile.

Uppdatering av berättelse • Dec 04

IVVD: REVOLUTION Program Launch Will Drive Future Regulatory And Commercial Upside

Analysts have raised their price target on Invivyd to $10 from $5, citing the launch of the REVOLUTION program for VYD2311 as a key inflection point that improves the company's regulatory and commercial outlook. Analyst Commentary Analysts interpreting the updated price target see the REVOLUTION program as a pivotal moment for Invivyd, shifting expectations for both execution and long term growth potential.

Analysartikel • Nov 29

Optimistic Investors Push Invivyd, Inc. (NASDAQ:IVVD) Shares Up 27% But Growth Is Lacking

Despite an already strong run, Invivyd, Inc. ( NASDAQ:IVVD ) shares have been powering on, with a gain of 27% in the...

Uppdatering av berättelse • Nov 20

IVVD: REVOLUTION Program Initiation Will Drive Regulatory Momentum and Commercial Outlook

Analysts have raised their price target for Invivyd from $5 to $10, citing the launch of the REVOLUTION clinical program as a pivotal development. This new program is expected to enhance the company's regulatory and commercial outlook.

Uppdatering av berättelse • Nov 05

IVVD: FDA Clearance and REVOLUTION Program Launch Signal Strong Upside Ahead

Narrative Update: Invivyd Analyst Price Target Increased Invivyd's analyst price target has been raised from $5.67 to $7.33 per share. Analysts cite strengthened commercial and regulatory prospects following the launch of the REVOLUTION clinical program.

Uppdatering av berättelse • Oct 22

Analysts Hold Invivyd Price Target Steady as FDA Progress and Valuation Metrics Update

Narrative Update on Invivyd: Analyst Price Target Revision Analysts have maintained Invivyd's price target at $5.67, citing consistent profit margin expectations along with only minor adjustments to the discount rate and future earnings estimates. What's in the News The FDA has cleared Invivyd's Investigational New Drug application, advancing the REVOLUTION clinical program for VYD2311, a monoclonal antibody candidate for COVID-19 prevention (Product-Related Announcements).

Analysartikel • Oct 14

Invivyd, Inc.'s (NASDAQ:IVVD) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Invivyd, Inc. ( NASDAQ:IVVD ) shares have continued their recent momentum with a 31% gain in the last month alone. The...

Uppdatering av berättelse • Oct 08

Internal Sales And Antibody Pipeline Will Broaden Patient Reach

Narrative Update on Invivyd Price Target Analysts have raised Invivyd’s price target from $3.00 to $5.67, citing updated forecasts and changes in market expectations. What's in the News The U.S. FDA cleared Invivyd’s Investigational New Drug application, enabling advancement of the REVOLUTION clinical program for VYD2311, a monoclonal antibody candidate for COVID-19 prevention (Key Developments).

Analysartikel • Aug 22

Why Investors Shouldn't Be Surprised By Invivyd, Inc.'s (NASDAQ:IVVD) 31% Share Price Plunge

Invivyd, Inc. ( NASDAQ:IVVD ) shareholders that were waiting for something to happen have been dealt a blow with a 31...

Uppdatering av berättelse • Aug 16

Internal Sales And Antibody Pipeline Will Broaden Patient Reach

Invivyd’s fair value estimate has been sharply reduced, driven by lowered revenue growth projections and a decline in expected net profit margins, resulting in a consensus analyst price target drop from $4.93 to $2.93. What's in the News Invivyd’s monoclonal antibody pemivibart (PEMGARDA) has shown strong protection (84% relative risk reduction) against symptomatic COVID-19 in immunocompromised and at-risk populations in the placebo-controlled CANOPY Phase 3 trial, supporting its Emergency Use Authorization (EUA) for pre-exposure prophylaxis.

Ny berättelse • Apr 23

Pemivibart And Next-Generation VYD2311 Will Empower Market Expansion By 2025

The development of next-generation antibodies could expand market reach and improve margins by lowering production and administration costs.

Seeking Alpha • Feb 04

I See The Bull Case For Invivyd, But I'm Not Married To It

Summary Invivyd, Inc. focuses on developing antibody-based treatments for infectious diseases, primarily COVID-19, with promising projects like PEMGARDA and VYD2311. Strong Q4 performance with a 48% revenue increase for PEMGARDA and a 55% drop in operating expenses highlights Invivyd's potential for profitability. VYD2311 shows significant promise with high neutralization potency and durability, but faces regulatory and competitive challenges before market approval. Invivyd is a speculative bet with potential for high rewards; suitable for risk-tolerant investors, but stability seekers should avoid. Read the full article on Seeking Alpha

Analysartikel • Feb 01

Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Analysartikel • Jul 16

Here's Why We're Watching Invivyd's (NASDAQ:IVVD) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Analysartikel • Mar 29

Is Invivyd (NASDAQ:IVVD) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, Invivyd ( NASDAQ:IVVD...

Analysartikel • Oct 24

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Aktieägarnas avkastning

	IVVD	US Biotechs	US Marknad
7D	0.2%	4.1%	1.6%
1Y	21.6%	41.1%	18.6%

Avkastning vs industri: IVVD presterade sämre än US Biotechs branschen som gav 41.1 % under det senaste året.

Avkastning vs Marknaden: IVVD översteg US marknaden som gav 18.6 % under det senaste året.

Prisvolatilitet

Is IVVD's price volatile compared to industry and market?
IVVD volatility
IVVD Average Weekly Movement	15.1%
Biotechs Industry Average Movement	10.3%
Market Average Movement	7.3%
10% most volatile stocks in US Market	16.7%
10% least volatile stocks in US Market	3.2%

Stabil aktiekurs: IVVD s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för US.

Volatilitet över tid: IVVD s veckovolatilitet ( 15% ) har varit stabil under det senaste året, men är fortfarande högre än 75 % av US aktier.

Om företaget

Grundad	Anställda	VD OCH KONCERNCHEF	Webbplats
2020	122	Bill Duke	www.invivyd.com

Invivyd, Inc. bedriver, tillsammans med sina dotterbolag, forskning, utveckling, kommersialisering och försäljning av antikroppsterapier för förebyggande och behandling av virala infektionssjukdomar i USA. Bolaget erbjuder Pemivibart, en monoklonal antikropp med förlängd halveringstid för förebyggande av covid-19 hos vuxna och ungdomar genom injektion före exponering, under varumärket PEMGARDA. Bolaget utvecklar också VYD2311, en monoklonal antikropp som befinner sig i klinisk fas III för förebyggande och behandling av SARS-CoV-2-virus, och VBY329, en monoklonal antikropp som befinner sig i preklinisk fas för förebyggande och behandling av respiratoriskt syncytialvirus och mässling hos nyfödda, spädbarn och barn.

Invivyd, Inc. Sammanfattning av grunderna

Hur förhåller sig Invivyd:s resultat och omsättning till dess börsvärde?
IVVD grundläggande statistik
Börsvärde	US$263.32m
Vinst(TTM)	-US$77.60m
Intäkter(TTM)	US$55.87m

4.7x

P/S-förhållande

-3.4x

P/E-förhållande

Är IVVD övervärderat?

Se Verkligt värde och värderingsanalys

Resultat & intäkter

Viktig lönsamhetsstatistik från den senaste resultatrapporten (TTM)
IVVD resultaträkning (TTM)
Intäkter	US$55.87m
Kostnad för intäkter	US$3.95m
Bruttovinst	US$51.92m
Övriga kostnader	US$129.52m
Intäkter	-US$77.60m

Senast redovisade vinst

Mar 31, 2026

Nästa vinstdatum

n/a

Vinst per aktie (EPS)	-0.26
Bruttomarginal	92.94%
Nettovinstmarginal	-138.90%
Skuld/egenkapitalförhållande	0%

Hur har IVVD utvecklats på lång sikt?

Se historisk utveckling och jämförelse

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/07/05 00:55
Aktiekurs vid dagens slut	2026/07/02 00:00
Intäkter	2026/03/31
Årlig intjäning	2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Invivyd, Inc. bevakas av 5 analytiker. 3 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Thomas Shrader	BTIG
Joshua Schimmer	Cantor Fitzgerald & Co.
Patrick Trucchio	H.C. Wainwright & Co.

Invivyd (IVVD) Aktievy

Belöningar

Riskanalys

Analyst Price Targets

Analysts Hold Invivyd Price Target Steady as FDA Progress and Valuation Metrics Update

Regulatory Risks And Competition Will Impede Gains But Yield Promise

Rapid Antibody Advances Will Leverage Secular Pandemic Trends

Top Analyst Narratives

Analysts Hold Invivyd Price Target Steady as FDA Progress and Valuation Metrics Update

Regulatory Risks And Competition Will Impede Gains But Yield Promise

Rapid Antibody Advances Will Leverage Secular Pandemic Trends

Invivyd, Inc. Konkurrenter

Keros Therapeutics

Korro Bio

X4 Pharmaceuticals

CapForce

Prishistorik och prestanda

Senaste nyheter och uppdateringar

IVVD: Phase 3 Prophylaxis Readouts And BLA Prospect Will Drive Upside

Invivyd, Inc. Completes Enrollment In Phase 3 Liberty Clinical Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine

Invivyd, Inc. Doses First Participants In Liberty Phase 3 Clinical Trial To Evaluate VYD2311 Antibody Versus Mrna Covid Vaccine and to Characterize Safety And Immunology Of Antibody and mRNA Vaccine Co-Administration

IVVD: Phase 3 Prophylaxis Progress And BLA Pathway Will Drive Upside

Consensus revenue estimates fall by 25%

First quarter 2026 earnings: EPS and revenues miss analyst expectations

Recent updates

IVVD: Phase 3 Prophylaxis Readouts And BLA Prospect Will Drive Upside

Invivyd, Inc. Completes Enrollment In Phase 3 Liberty Clinical Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine

Invivyd, Inc. Doses First Participants In Liberty Phase 3 Clinical Trial To Evaluate VYD2311 Antibody Versus Mrna Covid Vaccine and to Characterize Safety And Immunology Of Antibody and mRNA Vaccine Co-Administration

IVVD: Phase 3 Prophylaxis Progress And BLA Pathway Will Drive Upside

Consensus revenue estimates fall by 25%

First quarter 2026 earnings: EPS and revenues miss analyst expectations

Price target increased by 76% to US$10.00

Invivyd Sees Wider Loss and Share Decline as Pipeline Spending Rises and Revenue Misses Estimates

Invivyd Authors New Manuscript Evaluating Early Tolerability Of COVID Monoclonal Antibody And Comparing Results To COVID Vaccination

IVVD: Phase 3 COVID Prophylaxis Progress Will Drive Future Upside

IVVD: Phase 3 COVID Prophylaxis Progress Will Drive Future Upside

Invivyd, Inc Announces Progress in Revolution Program and Advancement of Novel Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

Invivyd, Inc., Annual General Meeting, May 19, 2026

IVVD: Phase 3 COVID Prevention And Long COVID Trial Will Drive Upside

Invivyd: A Logical Bull Thesis With A Major Catalyst Approaching

IVVD: Fast Track Phase 3 COVID Prevention Program Will Drive Future Upside

Invivyd, Inc. Appoints Michael Mina, M.D., Ph.D. As Chief Medical Officer

IVVD: Phase 3 Fast Track COVID Prevention Trials Will Support Future Upside

IVVD: Phase 3 Fast Track COVID Prevention Program Will Drive Future Upside

Invivyd Aligns with the U.S. Fda on Liberty, A Phase 3 Trial to Evaluate the Safety of Vyd2311 Antibody Versus Mrna Covid Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine

Invivyd, Inc.'s (NASDAQ:IVVD) 26% Share Price Plunge Could Signal Some Risk

IVVD: REVOLUTION Program Will Define Future Upside As COVID Prevention Alternative

Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026

IVVD: REVOLUTION Program And Fast Track Status Will Support Future Upside Potential

IVVD: REVOLUTION Program Launch Will Drive Future Regulatory And Commercial Upside

IVVD: REVOLUTION Program Launch Will Drive Future Regulatory And Commercial Upside

Optimistic Investors Push Invivyd, Inc. (NASDAQ:IVVD) Shares Up 27% But Growth Is Lacking

Invivyd, Inc. Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329

IVVD: REVOLUTION Program Initiation Will Drive Regulatory Momentum and Commercial Outlook

Invivyd, Inc. has completed a Follow-on Equity Offering in the amount of $124.9994 million.

IVVD: FDA Clearance and REVOLUTION Program Launch Signal Strong Upside Ahead

Analysts Hold Invivyd Price Target Steady as FDA Progress and Valuation Metrics Update

Invivyd, Inc.'s (NASDAQ:IVVD) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Internal Sales And Antibody Pipeline Will Broaden Patient Reach

Invivyd, Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application and Provide Feedback to Advance the Company's Revolation Clinical Program

Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors

Invivyd, Inc. Appoints Kristie Kuhl as Chief Communications Officer

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At Recover-TLC Workshop

Invivyd, Inc. has completed a Follow-on Equity Offering in the amount of $49.997866 million.

Why Investors Shouldn't Be Surprised By Invivyd, Inc.'s (NASDAQ:IVVD) 31% Share Price Plunge

Invivyd, Inc. has filed a Follow-on Equity Offering.

Invivyd, Inc. Announces Continued Neutralizing Activity of PEMGARDA®? (Pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG

Invivyd, Inc. Aligns with U.S. FDA on Rapid Pathway to Full Approval of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19

Internal Sales And Antibody Pipeline Will Broaden Patient Reach

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long Covid and Covid-19 Post-Vaccination Syndrome

Invivyd, Inc. Announces Positive Full Phase 1/2 Clinical Data for VYD2311, A Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

Invivyd Announces Publication of Landmark CANOPY Phase 3 Pemivibart Clinical Trial

Invivyd, Inc. Announces Inclusion of PEMGARDA (Pemivibart) in National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

Invivyd, Inc. Commends FDA Focus on Contemporary Evidence in Evaluating Medical Interventions to Prevent Covid-19

Invivyd, Inc. Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies for Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

Invivyd Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Pemivibart And Next-Generation VYD2311 Will Empower Market Expansion By 2025

Invivyd, Inc., Annual General Meeting, May 20, 2025

Invivyd, Inc. Appoints Ajay Royan, to Its Board of Directors